You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-EGFR antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adenocarcinoma of the Stomach Trial in Goyang (Anti-EGFR antibody in combination with weekly paclitaxel)

Recruiting
  • Adenocarcinoma of the Stomach
  • Anti-EGFR antibody in combination with weekly paclitaxel
  • Goyang, Gyeonggi, Korea, Republic of
    National Cancer Center
Nov 29, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Advanced Solid Tumors Trial in Shanghai (HLX07+Gemcitabine+Cisplatin, HLX07+Paclitaxel+Carboplatin, HLX07+mFOLFOX6)

Active, not recruiting
  • Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Shanghai East Hospital
May 5, 2022

NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

Recruiting
  • NSCLC
  • EGFR Gene Mutation
  • neo-antigen vaccine
  • Nanjing, China
    The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023

HLX07, nsqNSCLC, High EGFR Expression Trial in Shanghai (HLX07+carboplatin+pemetrexed, HLX07+docetaxel, HLX07)

Not yet recruiting
  • HLX07, nsqNSCLC, High EGFR Expression
  • Shanghai, China
    Shanghai Chest Hospital
Jul 5, 2022

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

Squamous Non-small-cell Lung Cancer Trial in Guangzhou (HLX10+chemo, HLX10+HLX07+chemo, HLX10+HLX07)

Recruiting
  • Squamous Non-small-cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
May 5, 2022

Solid Tumor Trial in Shanghai (HLX07)

Not yet recruiting
  • Solid Tumor
  • Shanghai, China
    Fudan University shanghai cancer center
May 3, 2022

NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

Not yet recruiting
  • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
  • MCLA-129: 1500mg or 2000mg IV Q2W
  • Befotertinib: 75 mg or 100 mg Po QD
  • Bengbu, Anhui, China
  • +2 more
Aug 28, 2023

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Cutaneous Squamous Cell Carcinoma Trial in Guangzhou (HLX07)

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Guangzhou, Guangdong, China
    Nanfang Hospital
Jun 15, 2022

Solid Tumor, Adult Trial (HLX35, HLX10)

Not yet recruiting
  • Solid Tumor, Adult
  • (no location specified)
Jun 29, 2022

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Trial in Charlottesville (EGFR BATs after

Recruiting
  • Locally Advanced Pancreatic Adenocarcinoma
  • Metastatic Pancreatic Adenocarcinoma
  • EGFR BATs after standard of care chemo
  • Charlottesville, Virginia
    University of Virginia
Mar 30, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (cetuximab (CTX) or nimotuzumab (NTZ))

Completed
  • Nasopharyngeal Carcinoma
  • cetuximab (CTX) or nimotuzumab (NTZ)
  • Shanghai, China
    Xiaoshen Wang
Mar 23, 2022

Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in Guanzhou (HLX07, HLX10, )

Not yet recruiting
  • Nasopharyngeal Carcinoma by AJCC V8 Stage
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 23, 2022

CRC Trial (HLX07, HLX10, mFOLFOX6)

Not yet recruiting
  • CRC
  • (no location specified)
May 1, 2022

Locally Advanced or Metastatic Solid Tumors, Squamous-cell NSCLC Trial in Shanghai, Xuzhou (HLX35)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Squamous-cell Non-small Cell Lung Cancer
  • Shanghai, China
  • +1 more
Jun 28, 2022

Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in New York, Charlottesville

Active, not recruiting
  • Pancreatic Cancer
  • +3 more
  • anti-EGFR-bispecific antibody armed activated T-cells
  • New York, New York
  • +1 more
Oct 7, 2021

Solid Tumor, Adult Trial in Germany, Italy, Spain (First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and

Completed
  • Solid Tumor, Adult
  • First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)
  • Berlin, Germany
  • +3 more
Jul 7, 2021

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, drug, biological)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Nov 30, 2022

EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)

Recruiting
  • EGFR NP_005219.2:p.S492R
  • +7 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023

Chordoma, Metastatic Chordoma, Unresectable Chordoma Trial in Houston (Cetuximab, Questionnaire Administration)

Recruiting
  • Chordoma
  • +2 more
  • Cetuximab
  • Questionnaire Administration
  • Houston, Texas
    M D Anderson Cancer Center
Jun 1, 2022

Small-cell Lung Cancer Trial in Changchun (HLX07, HLX10, carboplatin and etoposide)

Not yet recruiting
  • Small-cell Lung Cancer
  • Changchun, Jilin, China
    Jilin Cancer Hospital
May 3, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023